Molecular Biology of the Cell Sign up for new MBC in Press e-TOCs!

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Originally published as MBC in Press, 10.1091/mbc.E07-07-0649 on November 21, 2007

Vol. 19, Issue 2, 563-571, February 2008

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplemental Materials
Right arrow All Versions of this Article:
E07-07-0649v1
19/2/563    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Google Scholar
Right arrow Articles by Oganesian, A.
Right arrow Articles by Bornstein, P.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Oganesian, A.
Right arrow Articles by Bornstein, P.

Thrombospondins Use the VLDL Receptor and a Nonapoptotic Pathway to Inhibit Cell Division in Microvascular Endothelial Cells

Anush Oganesian*, Lucas C. Armstrong{dagger}, Mary M. Migliorini{ddagger}, Dudley K. Strickland{ddagger}, and Paul Bornstein*,§

Departments of *Biochemistry and §Medicine, University of Washington, Seattle, WA 98195; {dagger}Millipore, Temecula, CA 92590; and {ddagger}The Center for Vascular and Inflammatory Diseases, and the Departments of Surgery and Physiology, University of Maryland, Rockville, MD 20855

Submitted July 10, 2007; Revised October 10, 2007; Accepted November 9, 2007
Monitoring Editor: Josephine Adams

TSPs 1 and 2 function as endogenous inhibitors of angiogenesis. Although thrombospondins (TSPs) have been shown to induce apoptosis in HMVECs, we reasoned that a homeostatic mechanism would also be needed to inhibit EC growth without causing cell death, e.g., in the maintenance of a normal vascular endothelium. HMVECs, cultured in low serum, responded to VEGF with an increase in [3H]thymidine incorporation that was inhibited by TSPs and was accompanied by decreases in the phosphorylation of Akt and MAPK, without an increase in apoptosis. RAP, an inhibitor of the low-density lipoprotein (LDL) family of endocytic receptors, and blocking antibodies to VLDLR were as effective as TSPs in the inhibition of thymidine uptake in response to VEGF, and the effects of these agents were not additive. Supportive evidence for the role of the VLDLR in mediating this inhibition was provided by the demonstration of a high-affinity interaction between TSPs and the VLDLR. We propose that TSP1 and TSP2, together with the VLDLR, initiate a nonapoptotic pathway for maintenance of the normal adult vascular endothelium in a quiescent state, similar to that invoked for the regulation of mitogenesis by PDGF, but involving signaling via the VLDLR rather than LRP1.


This was published online ahead of print in MBC in Press (http://www.molbiolcell.org/cgi/doi/10.1091/mbc.E07-07-0649) on November 21, 2007.

Address correspondence to: Paul Bornstein (bornsten{at}u.washington.edu)

Abbreviations used: EC, endothelial cell; HUVEC, human umbilical vein endothelial cell; HMVEC, human microvascular endothelial cell; LDL, low-density lipoprotein; LRP1, low-density lipoprotein–related protein-1; MAPK, mitogen-activated protein kinase; PDGF, platelet-derived growth factor; PTB, phosphotyrosine-binding; RAP, receptor-associated protein; TSP, thrombospondin; VEGF, vascular endothelial growth factor; VEGFR, VEGF receptor 2; VLDL, very low density lipoprotein; VLDLR, VLDL receptor.







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Copyright © 2008 by The American Society for Cell Biology. Terms of copyright protection, warranties, and disclaimers.